CCO Treatment Updates
Management of Recurrent Epithelial Ovarian Cancer: Current Standards and Novel Approaches
Virtual Presentations
View this symposium on your computer! These on-demand presentations include both the slides and audio from the key presentations given at this Satellite Symposium, entitled Management of Recurrent Epithelial Ovarian Cancer: Current Standards and Novel Approaches. The symposium was held on March 5, 2007.
Management of Recurrent Epithelial Ovarian Cancer: Therapeutic Approaches for the Relapsed Platinum-Resistant Patient
CME Program Director:
Susan C. Modesitt, MD
|
|
 Listen to Bradley J. Monk, MD, present an overview of optimal management of patients with recurrent, platinum-resistant ovarian cancer, including data on approved and investigational treatment options. Learning Objectives
Upon completion of this activity, participants should be able to:
- List the range of current treatment options for recurrent, platinum-resistant ovarian cancer
- Describe recent clinical trials evaluating single-agent and combination regimens for recurrent, platinum-resistant ovarian cancer
- Discuss the rationale for use of novel agents in combination with standard chemotherapeutic agents in patients with recurrent ovarian cancer
|
Management of Recurrent Epithelial Ovarian Cancer: Current Standards in Patients With Platinum-Sensitive Disease
CME Program Director:
Susan C. Modesitt, MD
|
|
Listen to J. Tate Thigpen, MD, present an overview of optimal management of platinum-sensitive recurrent ovarian cancer, including data on approved and investigational treatment options. Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the significance of the treatment-free interval following initial platinum-based chemotherapy in patients with advanced ovarian cancer
- List current treatment options for recurrent, platinum-sensitive ovarian cancer
- Describe recent clinical trials evaluating single-agent and combination regimens for recurrent, platinum-sensitive ovarian cancer
|
Management of Recurrent Epithelial Ovarian Cancer: Future Directions and New Frontiers in Individualized Therapeutic Approaches
CME Program Director:
Susan C. Modesitt, MD
|
|
Listen to Judith K. Wolf, MD, describe future directions in management of recurrent ovarian cancer, including a discussion of screening and individualized therapeutic approaches. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe data supporting the potential role of chemoresponse assays and other modalities in predicting response to ovarian cancer therapy
- Discuss the rationale for use of novel agents in patients with recurrent ovarian cancer
- Explain the relative merits of various options for ovarian cancer screening
|
CCO Slidesets
This slideset was presented at a Satellite Symposium, titled Management of Recurrent Epithelial Ovarian Cancer: Current Standards and Novel Approaches, held on March 5, 2007.
Current Approaches and Future Directions in the Treatment of Platinum-Sensitive or Platinum-Resistant Recurrent Ovarian Cancer
 |
|
Format: Microsoft PowerPoint (.ppt) | File size: 1,710 KB
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by University of Virginia School of Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|